Anti-TGF-beta Therapy in Patients With Myelofibrosis
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2011 |
Phase I Study of GC1008 in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera/Essential Thrombocythemia Related Myelofibrosis (Post-PV/ET MF)
TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with
myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and
myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The
investigators propose that inhibiting the TGF-β signaling pathway in MF will decrease the
fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation.
This is a noverl approach to the treatment of patients with myelofibrosis.
We found this trial at
2
sites
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
Click here to add this to my saved trials
Mayo Clinic Scottsdale Mayo Clinic Arizona was the second Mayo practice to be established outside...
Click here to add this to my saved trials